Anika Therapeutics Inc (NAS:ANIK)
$ 16.9601 0.6601 (4.05%) Market Cap: 248.39 Mil Enterprise Value: 201.25 Mil PE Ratio: 0 PB Ratio: 1.39 GF Score: 80/100

Q4 2022 Anika Therapeutics Inc Earnings Call Transcript

Mar 06, 2023 / 10:00PM GMT
Release Date Price: $28.87 (-8.61%)
Operator

Greetings, and welcome to Anika's Fourth Quarter and Year-End 2022 Earnings Conference Call. (Operator Instructions)

It is now my pleasure to introduce your host, Mark Namaroff, Vice President, Investor Relations, ESG and Corporate Communications. Thank you. You may begin.

Mark Namaroff
Anika Therapeutics, Inc. - Executive Director of IR & Corporate Communications

Thank you very much. Thank you, good evening, everyone. Thank you for joining us for Anika's fourth quarter and year-end conference call and webcast. Our Q4 earnings press release was issued after the close of the market today and is available on our Investor Relations website located at anika.com as are the supplementary PowerPoint slides that will be used for the discussion today.

With me on the call today are Dr. Cheryl Blanchard, President and Chief Executive Officer; and Mike Levitz, Executive Vice President, Chief Financial Officer and Treasurer.

Please take a moment and open the slide presentation and refer to Slide number2. Before we begin, please understand

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot